Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasm, Residual 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphoma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

fludarabine 4Cyclophosphamide 4fludarabine phosphate 3Melphalan 3pembrolizumab 2obinutuzumab 2blinatumomab 2Rituximab 2Radiotherapy 2Lenalidomide 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1tislelizumab 1tisagenlecleucel 1thymoglobulin 1tetrathiomolybdate 1talquetamab 1sacituzumab govitecan 1palbociclib 1nilotinib 1isatuximab 1avelumab 1atezolizumab 1acalabrutinib 1Whole-Body Irradiation 1Trastuzumab 1Sirolimus 1Neoadjuvant Therapy 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × Biological Assay × 90 days × Clear all
NCT05642195 2026-06-05

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Suspended
30 enrolled
Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡